## Polycyclitols. Novel conduritol and carbasugar hybrids as a new class of potent glycosidase inhibitors


## Goverdhan Mehta\* and Senaiar S. Ramesh

Department of Organic Chemistry, Indian Institute of Science, Bangalore, 560 012, India

Received (in Cambridge, UK) 6th September 2000, Accepted 31st October 2000 First published as an Advance Article on the web 22nd November 2000


We have conceptualized new molecular entities (bicyclitols) in which two conduritol and two carbasugar moieties are embedded in a polyhydroxylated decahydronaphthalene framework and achieved their syntheses in a stereo- and regioselective manner. One of the bicyclitols was found to be a potent and selective  $\alpha$ -glucosidase inhibitor.

Conduritols 1 (six diastereomers designated A-F are known)<sup>1</sup> and carbasugars 2 are a class of polyhydroxylated cyclohexanoids that have evoked a great deal of synthetic interest in recent years.<sup>1,2</sup> In view of their promising therapeutic potential in the management of wide ranging disorders like diabetes, viral infections, HIV and cancer among others, many analogues and structural variants of 1 and 2 have been synthesized and their biological activities, particularly glycosidase inhibition has been evaluated.<sup>3</sup> Considering the fundamental importance of competitive and specific glycosidase inhibition in new drug development, we have conceived of a new family of polyhydroxylated polycyclic systems (polycyclitols) represented by **3** as potential glycomimics.<sup>4</sup> Bicyclitol **3** is an interesting entity which can be considered as a hybrid of two conduritols with shared, common ring junction carbon atoms. Alternately, 3 can be regarded as a hybrid of two carbasugars A and B (see, bold portions in 4 and  $\overline{5}$ ), both of which are ring annulated. Herein,




we report the stereo- and regioselective syntheses of two polycyclitols 6 and 7 based on the general structure 3, and show that one of them 6 is a potent and selective inhibitor of  $\alpha$ -glucosidase.

Our synthesis of **6** emanated from the readily available Diels– Alder adduct **8** of 5,5-dimethoxy-1,2,3,4-tetrachlorocyclopentadiene and *p*-benzoquinone, which was elaborated to the tricyclic diene **9** following the tactically modified literature procedure.<sup>5</sup> Exhaustive OsO<sub>4</sub> mediated dihydroxylation of **9** occurred exclusively from the *exo*-face to furnish the all *cis*tetrol **10**.<sup>6</sup> Selective monoprotection and reductive dechlorination in **10** led to the symmetrical **11**.<sup>6</sup> Careful deketalisation in **11**, while retaining the acetonide protective group led to the desired norbornen-7-one† **12**, Scheme 1. Thermally induced decarbonylation in **12** to the cyclohexadiene derivative **13**<sup>6</sup> was smooth and further catalytic,  $OsO_4$  mediated double dihydroxylation proceeded stereoselectively to furnish **14** as a single diastereomer. Acetonide deprotection in **14** provided the octahydroxydecahydronaphthalene **6**,<sup>6</sup> a hybrid of conduritols D (right ring) and E (left ring), Scheme 1. The absence of symmetry in **6** and **14**, revealed through the presence of 10 and 13 lines, respectively, in the <sup>13</sup>C NMR spectra, uniquely settled the stereochemical pattern present in these bicyclitols. Bicyclitol **6** was screened against  $\alpha$ - and  $\beta$ -glucosidases (from Bakers' yeast and almonds, respectively) that accept corresponding *p*nitrophenylglycosides as substrates and it was very satisfying to find impressive inhibition of  $\alpha$ -glucosidase with a  $K_i$  value<sup>7</sup> of 12  $\mu$ M (*cf.*  $K_i = 25.4 \mu$ M for deoxynojirimycin, DNJ). Interestingly, **6** exhibited no significant inhibitory activity



Scheme 1 Reagents and conditions: i,  $OsO_4$  (cat.), NMMO,  $Me_2CO:tBuOH$  (5:2), 2 d, 66%; ii, (*a*) Amberlyst-15, acetone, mol. sieves 4 A, 75%; (*b*) Na, liq. NH<sub>3</sub>, THF, EtOH, 49%; iii, Amberlyst-15, acetone, 98%; iv,  $C_6H_5NO_2$ , 160 °C, 62%; v,  $OsO_4$  (cat.), NMMO,  $Me_2CO:H_2O:tBuOH$  (5:5:2), 85%; vi, 30% CF<sub>3</sub>COOH, 95%.



Scheme 2 *Reagents and conditions*: i, Amberlyst-15, acetone, 95%; ii,  $C_6H_5NO_2$ , 160 °C, 34%; iii,  $OsO_4$  (cat.), NMMO,  $Me_2CO:H_2O:tBuOH$  (5:5:2), 73%; iv, 30% CF<sub>3</sub>COOH, 90%.

against  $\beta$ -glucosidase at mM concentration, thus highlighting its selectivity towards  $\alpha$ -glucosidase.

The promising inhibitory profile of 6, spurred us to prepare a diastereomer 7 of 6. Diels-Alder adduct 8 was readily transformed to the endo, endo-diol-15.6 Deketalisation to 16 and decarbonylation led to the cyclohexadiene derivative 17,6 Scheme 2. Catalytic OsO<sub>4</sub> mediated double dihydroxylation was once again highly diastereoselective and the hexahydroxyacetal 18 was obtained. Acetonide deprotection in 18 delivered the projected bicyclitol 7,6 a hybrid of conductors A (right ring) and E (left ring). Once again the lack of symmetry (13C NMR) in 7 and 18, uniquely delineated the stereochemical pattern generated during the double dihydroxylation of 17. When 7 was evaluated for its inhibitory activity against  $\alpha$ - and  $\beta$ -glucosidases, no significant inhibition was observed for either of the enzymes at mM concentrations, indicating that stereochemical alterations in the hydroxy substituents has a major impact on the enzyme inhibitory activity (cf. 6). This result provides further impetus to prepare many more diastereomers of 6 and 7 for further evaluation and efforts towards that end are underway.

In short, we have devised a new family of glycosidase inhibitors, composed of conduritol and carbasugar hybrid structures and describe the synthesis of an octahydroxydeca-hydronaphthalene, which exhibits significant and selective  $\alpha$ -glucosidase activity.

We thank JNCASR for financial support and the SIF facility at I.I.Sc for the high field NMR spectra. One of us (SSR) thanks CSIR for a research fellowship. We thank Dr Utpal Tatu, Department of Biochemistry for help in enzymatic assays.

## Notes and references

† The IUPAC name for norbornen-7-one is bicyclo[2.2.1]hept-2-en-7-one.

- (a) M. Balci, Y. Sutbeyaz and H. Secen, *Tetrahedron*, 1990, **46**, 3715; (b)
   H. A. J. Carless, *Tetrahedron: Asymmetry*, 1992, **3**, 795; (c) M. Balci, *Pure Appl. Chem.*, 1997, **69**, 97.
- (a) T. Suami, *Top. Curr. Chem.*, 1990, **154**, 257; (b) R. J. Ferrier and S. Middleton, *Chem. Rev.*, 1993, **95**, 2779; (c) T. Hudlicky, D. A. Entwistle, K. K. Pitzer and A. J. Thorpe, *Chem. Rev.*, 1996, **96**, 1195; (d) C. R. Johnson, *Acc. Chem. Res.*, 1998, **31**, 333; (e) Y. Landais, *Chimia*, 1998, **52**, 104.
- 3 (a) B. Ganem, Acc. Chem. Res., 1996, 29, 340; (b) M. Bols, Acc. Chem. Res., 1998, 31, 1.
- 4 For a few related examples of syntheses of annulated conduritols, see: (a) D. C. Billington, F. Perron-Sierra, I. Picard, S. Beaubras, J. Duhault, J. Espinal and S. Challal, *Bioorg. Med. Chem. Lett.*, 1994, **4**, 2307; (b) Y. Kara, M. Balci, S. A. Bourne and W. H. Watson, *Tetrahedron Lett.*, 1994, **35**, 3349; (c) M. Desjardins, M. C. Lallemand, T. Hudlicky and K. A. Abboud, *Synlett.*, 1997, **728**; (d) G. Mehta and D. S. Reddy, *Tetrahedron Lett.*, 1999, **40**, 9137; (e) G. Mehta, D. S. Reddy, S. S. Ramesh and U. Tatu, *Tetrahedron Lett.*, 1999, **40**, 9141.
- 5 (a) M. A. Forman and W. P. Dailey, J. Org. Chem., 1993, 58, 1501; (b) T.-C Chou and J. H. Chiou, J. Chin. Chem. Soc. (Tapei), 1986, 33, 227.
- 6 All the new compounds reported here were fully characterised on the basis of their spectral IR, <sup>1</sup>H and <sup>13</sup>C NMR, MS) and analytical data. Selected spectral data: **13**: δ<sub>H</sub>(300 MHz; CDCl<sub>3</sub>) 5.87–5.83 (m, 2H), 5.65–5.61 (m, 2H), 4.42–4.40 (m, 2H), 3.74 (br s, 2H), 3.00–2.98 (m, 2H), 2.70–2.67 (m, 2H), 1.55 (s, 3H), 1.40 (s, 3H); δ<sub>C</sub>(75 MHz; CDCl<sub>3</sub>) 125.8(2C), 122.6(2C), 109.3, 74.8(2C), 69.0(2C), 35.4(2C), 26.0, 24.4. 6: δ<sub>H</sub>(300 MHz; D<sub>2</sub>O), 4.00–3.60 (m, 2H), 2.22–2.18 (m, 2H); δ<sub>C</sub>(100 MHz; D<sub>2</sub>O) 77.0, 76.7, 76.0, 74.2, 73.2, 71.2 (2C), 66.4, 43.1, 40.5; MS (70 eV, EI): *m/z* 264 (M<sup>+</sup> 2). **17**: δ<sub>H</sub>(300 MHz; CDCl<sub>3</sub>) 5.97–5.94 (m, 2H), 5.54–5.50 (m, 2H), 4.50–4.49 (m, 2H), 3.36 (br s, 2H), 3.53 (d, 2H, J = 6.9 Hz), 3.20 (br s, 2H), 1.46 (s, 3H), 1.37 (s, 3H); δ<sub>C</sub>(75 MHz; CDCl<sub>3</sub>) 125.8(2C), 123.8(2C), 108.6, 74.9(2C), 69.7(2C), 32.4 (2C), 26.6, 24.0.
  7: δ<sub>H</sub>(300 MHz; D<sub>2</sub>O) 4.00–3.67 (m, 8H), 2.36–2.28 (m, 2H); δ<sub>C</sub>(75 MHz; DL)
- 7 Each enzymatic assay contained  $\alpha$  or  $\beta$ -glucosidase (0.1 to 1.0 U ml<sup>-1</sup>), compounds **6**/7 in water and the corresponding *p*-nitrophenylglycosides (2–3 mM) at a pH and temperature optimum for the enzyme.  $K_i$  ( $\mu$ M) values were determined using Lineweaver–Burk plots of the inhibition data.